ArriVent BioPharma’s (AVBP) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of ArriVent BioPharma (NASDAQ:AVBP) in a research note released on Friday morning,Benzinga reports. The brokerage currently has a $36.00 target price on the stock.

Several other equities analysts also recently issued reports on AVBP. The Goldman Sachs Group lifted their price objective on ArriVent BioPharma from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Tuesday, September 10th. Oppenheimer reissued an “outperform” rating and set a $39.00 price objective (up previously from $35.00) on shares of ArriVent BioPharma in a report on Tuesday, September 10th. Finally, Citigroup boosted their target price on shares of ArriVent BioPharma from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, ArriVent BioPharma currently has an average rating of “Buy” and an average target price of $36.80.

ArriVent BioPharma Trading Down 3.1 %

Shares of NASDAQ:AVBP opened at $27.21 on Friday. The business’s fifty day moving average price is $28.01 and its two-hundred day moving average price is $23.13. ArriVent BioPharma has a fifty-two week low of $14.35 and a fifty-two week high of $36.37.

Institutional Trading of ArriVent BioPharma

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. bought a new position in shares of ArriVent BioPharma during the first quarter worth $11,586,000. AlphaCentric Advisors LLC lifted its holdings in ArriVent BioPharma by 3.6% during the second quarter. AlphaCentric Advisors LLC now owns 86,000 shares of the company’s stock worth $1,595,000 after acquiring an additional 3,000 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in ArriVent BioPharma in the first quarter valued at about $83,000. Novo Holdings A S increased its holdings in shares of ArriVent BioPharma by 39.3% in the second quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $27,825,000 after acquiring an additional 422,860 shares in the last quarter. Finally, American International Group Inc. bought a new stake in shares of ArriVent BioPharma in the first quarter worth about $87,000. 9.48% of the stock is currently owned by institutional investors and hedge funds.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.